Vertex Pharmaceuticals (VRTX) closed the latest trading day at $484.94, indicating a +0.67% change from the previous session's end. This move lagged the S&P 500's daily gain of 0.77%. On the other hand, the Dow registered a gain of 0.47%, and the technology-centric Nasdaq increased by 0.87%. The drugmaker's shares have seen a decrease of 0.75% over the last month, surpassing the Medical sector's loss of 3% and falling behind the S&P 500's gain of 4.87%. Analysts and investors alike will be keeping a close e ...

Vertex Pharmaceuticals (VRTX) closed at $465.08 in the latest trading session, marking a +0.48% move from the prior day. This move outpaced the S&P 500's daily gain of 0.42%. Meanwhile, the Dow experienced a rise of 0.04%, and the technology-dominated Nasdaq saw an increase of 0.38%. The drugmaker's stock has dropped by 6.66% in the past month, falling short of the Medical sector's loss of 2.49% and the S&P 500's gain of 2.06%. The upcoming earnings release of Vertex Pharmaceuticals will be of great interes ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) . Vertex currently has an average ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this drugmaker have returned -3.6%, compared to the Zacks S&P 500 composite's +2% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Vertex falls in, has lost 1.5%. The key question now is: What could be the stock's future direction? ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Cantor Global Healthcare Conference September 17, 2024 9:10 AM ET Company Participants Susie Lisa - SVP, IR Manisha Pai - Executive Director, IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Olivia Brayer Joining us this morning at our Cantor Global Healthcare Conference. Really excited to have another year of it. My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with u ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Cantor Global Healthcare Conference September 17, 2024 9:10 AM ET Company Participants Susie Lisa - SVP, IR Manisha Pai - Executive Director, IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Olivia Brayer Joining us this morning at our Cantor Global Healthcare Conference. Really excited to have another year of it. My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with u ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this drugmaker have returned +1.4% over the past month versus the Zacks S&P 500 composite's +4.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has gained 3.7% over this period. Now the key question is: Where could the stock be headed in ...

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) Morgan Stanley Conference Call September 5, 2024 11:30 AM ET Company Participants Reshma Kewalramani - President and CEO Charlie Wagner - CFO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclos ...

Vertex Pharmaceuticals has a lot going for it. Novo Nordisk (NVO 1.42%) is enjoying one of the best seasons in its history. Two of the company's drugs, Ozempic and Wegovy, have become household names. Novo's sales and profits are soaring. So is its share price, with the stock up around 150% over the last three years. Some investors who didn't buy Novo Nordisk earlier could be considering jumping on the bandwagon now. I have an alternate idea. Forget Novo Nordisk and buy another magnificent pharma stock inst ...

Vertex Pharmaceuticals Incorporated (VRTX) enjoys a dominant position in the cystic fibrosis (CF) market. In the first half of 2024, Vertex's CF revenues rose almost 10%, driven by the continued strong performance of Trikafta/Kaftrio, including in younger age groups. While in the near term, expansion to younger age groups should drive CF sales growth, the potential launch of Vertex's fifth CFTR modulator therapy, vanzacaftor triple combination, should drive growth in the medium term. While CF remains the ma ...